
    
      This is a Phase 1, open-label, randomized, 2-way crossover study in 96 healthy adult
      participants. The study consists of 2 treatment sessions. Participants will receive in one
      session a single dose of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF)
      800/150/200/10 milligram (mg) tablets as fixed-dose combination (FDC) and in another session
      Darunavir (DRV) as 1x 800 mg tablet, Emtricitabine/ tenofovir alafenamide (FTC/TAF) as 1x
      200/10 mg FDC tablet, and Cobicistat (COBI) 150 mg as 1x 150 mg tablet all under fed
      conditions. Treatment sessions will be separated by a washout period of at least 7 days. The
      duration of the study for an individual participant will be at least 12 days, Screening and
      Follow-up not included. Participants safety will be monitored throughout the study.
    
  